Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in ...
Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing. | Scribe Therapeutics has put its IPO plans down on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results